Understand the findings.
Know your options and when to seek help.
Based on published clinical guidance · Last updated 29 October 2026
Age-related macular degeneration, or AMD, affects the macula, the central area of the retina used for detailed vision. Changes can make reading, recognising faces and judging fine detail harder. It affects the back of the eye rather than creating a film on its surface, and a glasses prescription alone cannot establish the stage or explain every symptom. [12]
AMD does not usually remove all peripheral vision, but central loss can still have a major effect on everyday life. People may have trouble finding the start of a word, seeing a face clearly or noticing a small object directly ahead. Ask about practical visual support early rather than waiting until ordinary tasks become impossible. [12][14]
An assessment identifies the type and stage of AMD and checks for other eye disease. The Irish HSE/ICO care model includes distortion or loss of vision among reasons for referral. Describe changes in your own words, including which eye is affected and when the problem started; a precise history helps determine how quickly further assessment is needed. [2]
Dry AMD includes changes such as deposits called drusen, pigment changes and, in later disease, areas of retinal tissue loss called geographic atrophy. Its course varies. A dry diagnosis is not a guarantee that sight will remain unchanged, and it should not be used to dismiss a new symptom without looking for another explanation. [4]
Wet AMD involves abnormal blood vessels beneath the macula that can leak fluid or bleed. The ICO leaflet explains this mechanism, while current specialist guidance emphasises early detection and prompt treatment. Wet disease can damage central sight quickly, so a new distorted area or central patch should prompt advice rather than waiting for a routine eye test. [1][4]
The labels need careful interpretation. An eye previously treated for wet AMD may become inactive, but NICE advises against simply calling inactive wet disease dry AMD. Ask whether there is active leakage, old damage or atrophy, because these findings lead to different monitoring and treatment discussions even when the symptom is described as blur. [3]
New wavy or crooked straight lines, a blurred or grey central patch, or a change in the apparent size of objects needs prompt eye-care advice. NICE lists these changes for self-monitoring. Tell the team whether the problem is new or clearly different from your usual sight; a previous dry-AMD diagnosis does not establish that the change is harmless. [3][13]
AMD is usually painless and does not alter the outward appearance of the eye. This makes symptoms easy to overlook, particularly when the other eye sees better. Checking each eye separately can reveal a change that is less obvious with both eyes open. Pain, redness or a sudden curtain suggests other urgent possibilities that also need assessment. [13]
Some people with significant sight loss see shapes, patterns or images that are not actually present. NICE includes discussion of Charles Bonnet syndrome in AMD information. Report these experiences to a clinician so the circumstances can be assessed and support offered. They should not automatically be attributed to AMD without considering other symptoms and possible causes. [3]
In general clinical guidance, assessment considers visual acuity and examination of the macula, often after pupil dilation. The clinician looks for deposits, pigment change, atrophy, fluid or bleeding and considers other causes of reduced sight. Bring previous scans and treatment records if available. A photograph or scan is most useful when interpreted with your symptoms and examination. The tests described here are general diagnostic methods, not a promised first-visit package. [4]
OCT produces cross-sectional retinal images and is recommended by NICE when active wet AMD is suspected. It can show fluid and help monitor activity during treatment. The result informs the plan, but a stable scan does not automatically explain a new decline in sight; further examination or a different test may still be needed. [3][4]
Dye imaging may be useful when the diagnosis or abnormal vessels remain uncertain. Not everyone needs it, and the purpose should be explained before testing. Ask whether dilation or the planned investigation will affect your journey home. A general description of testing does not establish a clinic-specific device, appointment duration or required test package. [3]
Increasing age and family history can increase AMD risk, while smoking is an important modifiable factor. AAO strongly recommends smoking cessation for people with AMD or at risk of it. These associations do not mean you caused the disease, and having affected relatives does not establish that you already have AMD or predict your individual course. [4]
A balanced diet, physical activity and appropriate management of general health can support eye health. They do not reverse established macular damage or replace assessment of a new symptom. NEI recommends discussing risk and regular eye examinations, particularly when age or family history is relevant. Avoid assuming that a healthy diet makes monitoring unnecessary. [12]
Routine genetic testing is not needed to decide whether standard AREDS-based supplementation is appropriate. NEI and AAO emphasise the clinical findings rather than using a commercial genetic result to select a supplement. Bring your medicine and supplement list so the discussion includes possible interactions and avoids taking overlapping high-dose products without a clear reason. [11][4]
AREDS2 supplements are considered for specific stages, particularly intermediate AMD, rather than everyone who is worried about ageing eyes. The original AREDS trial supported antioxidants and zinc in selected higher-risk groups. Supplements do not prevent all AMD, repair lost central vision or replace injections for active wet disease. Your diagnosis and stage determine whether a supplement discussion is useful. [7][10]
NEI explains that the original AREDS formula reduced the chance of advanced AMD by about 25% over five years in the relevant study groups. This means a lower chance of progression compared with the comparison group, not 25% better eyesight or a guarantee against deterioration. The often-quoted figure comes from AREDS; AREDS2 subsequently examined changes to that formulation. [11]
AREDS2 supports replacing beta-carotene with lutein and zeaxanthin, especially because beta-carotene raises concern about lung cancer in people who have smoked. Longer follow-up supports this replacement. The original AREDS2 comparison did not show that adding every extra ingredient produced another overall benefit, so avoid treating the supplement name as a promise that more ingredients are always better. [8][9]
Cochrane finds that people with intermediate AMD are more likely to benefit than those with early disease. Check suitability and interactions before buying a high-dose product. An ordinary multivitamin is not automatically equivalent, and a supplement does not take the place of a varied diet. Tell the clinician about smoking history even if you stopped long ago. [6][10]
Our clinic offers intravitreal anti-VEGF injections when clinically appropriate. Anti-VEGF injections are the main treatment for active wet AMD. They reduce signals involved in abnormal vessel growth and leakage, aiming to protect sight and sometimes improve it. Treatment reaches the back of the eye by injection. The expected benefit depends on activity, existing damage and the whole eye; recovering all lost vision cannot be promised. [4][15]
Cochrane’s review supports anti-VEGF treatment for maintaining vision, with improvement in some treated eyes. Its comparisons cover particular medicines and treatment schedules, not every newer option. The choice of medicine and timing should reflect the evidence, safety, response and practical circumstances. A published average should not be presented as this clinic’s success rate or an individual forecast. [5]
A course of treatment and ongoing monitoring are commonly needed. The team uses sight, OCT and examination to judge activity and decide whether to continue, adjust or pause treatment. Explain transport difficulties or missed appointments early. Do not assume that feeling better means an injection can be skipped without discussion, or that every visit must involve an injection. [4][15]
Advanced dry AMD requires a different discussion from wet disease. Geographic atrophy represents areas of macular tissue loss, rather than leakage from new vessels. Management considers the diagnosis, remaining visual function and current evidence. Anti-VEGF injections used for wet AMD should not be assumed to treat atrophy, and a dry label alone does not settle every treatment option. [4]
Treatments and devices for atrophic AMD are evolving, and evidence about slowing tissue change is different from evidence that sight improves. AAO discusses newer approaches alongside their limitations. An overseas approval or a study result does not establish availability in Ireland or suitability for your eye. Ask what benefit and risks are supported for the proposed approach. [4]
Low-vision assessment, rehabilitation and practical support remain valuable whether or not a medical treatment is offered. NHS information describes support for living with AMD, including help using remaining sight. Improving lighting, choosing suitable magnification and adapting reading methods can make tasks more manageable. These measures are part of care rather than a sign that further concerns should be ignored. [14]
An Amsler grid helps you notice changes such as wavy, missing or blurred lines. AAO advises checking daily, with reading glasses if normally needed, looking at the central dot and covering the other eye. Check each eye separately. Ask your eye-care professional to show you a suitable grid and how to record a change from your usual view. [16]
Contact your eye-care professional promptly if a new area looks distorted, blank or blurred. The grid supports noticing change; it does not replace OCT, a retinal examination or scheduled monitoring. A normal-looking grid cannot exclude every problem, particularly if you have noticed a new symptom during reading or other ordinary tasks. [16][3]
The page’s central-patch simulator and example grid are educational illustrations. Their controls do not measure your macula, assign a clinical stage or reproduce every person’s sight. Switch off the example distortion before viewing the ordinary grid. Screen size and viewing conditions vary, so use the instructions and monitoring method agreed with your eye-care professional for actual home checks. [16][4]
Adjust an example of a central patch while the surrounding scene remains visible.
Scene without an overlay
Keep looking at the central dot. The toggle deliberately adds distortion so you can explore the idea.
Example distortion is off.
Ask about low-vision support when reading, recognising faces or household tasks become difficult. Practical assessment can consider magnification, contrast, lighting and ways to use the clearer parts of your vision. Losing central detail does not necessarily mean losing all sight. Support can be useful during active treatment as well as when retinal damage is longstanding. [12][14]
Driving depends on measured visual function and the relevant licensing requirements, not simply on an AMD label. Do not use the simulator or a familiar driving route to judge whether you meet the standard. Mention glare, difficulty recognising signs and any recent change to your eye-care professional, particularly if treatment or dilation affects sight around an appointment. [3][13]
Bring your glasses, medicine list and details of previous injections to consultations. Tell the team how vision affects reading, work, falls risk or caring responsibilities. It can help to bring someone who supports you, with your permission. NICE recommends accessible information and attention to practical and emotional needs, not just a scan-based treatment decision. [3]
New central distortion or a grey patch needs prompt assessment because active wet AMD is possible. Current AAO guidance links early detection and prompt treatment with better visual outcomes. Do not wait for a routine review simply because the eye is painless or because a previous diagnosis was dry AMD. Explain that the symptom is new or worsening. [4][1]
Sudden major loss of vision, a curtain-like shadow or a painful red eye needs urgent assessment for other serious causes as well. Contact an appropriate urgent eye service; if you cannot obtain prompt advice, attend an emergency department. Do not drive yourself with impaired vision. A self-checking grid cannot decide whether an acute symptom is safe to leave. [13]
After an injection, worsening pain, increasing redness, discharge or reduced sight needs urgent contact with the treating team. Serious infection or another complication must be considered. Follow the written return advice and use emergency services if the team is unavailable. Mild expected discomfort is different from symptoms that are becoming more severe or affecting vision. [15]
At Limerick Eye Clinic
Macular assessment and intravitreal anti-VEGF injections when clinically appropriate, with treatment and monitoring tailored to your response.
Retinal laser and retinal surgery are not performed at our clinic. If they are suitable for you, we arrange onward care.
Your glasses, a list of your medicines and any previous letters or reports. A referral letter can be uploaded with your appointment request.
+353 61 52 6664
reception@limerickeyeclinic.ie
AMD is damage to the macula, the part of the retina used for sharp central vision. NEI explains that it can affect reading, recognising faces and other detailed tasks. It does not usually remove all peripheral vision, but central loss can still be disabling. An examination establishes the type and stage and checks for other causes of visual difficulty. [12]
Dry AMD involves deposits, pigment changes or areas of tissue loss; wet AMD involves abnormal vessels that leak or bleed beneath the macula. ICO describes the wet mechanism, and current AAO guidance stresses prompt assessment of active disease. The labels do not predict every person’s course, so ask what is actually present in your eye. [1][4]
AMD usually affects central vision rather than all peripheral sight, so it does not normally cause complete blindness by itself. NEI makes this distinction while recognising the serious effect of central loss on daily life. Your outlook depends on the stage and other eye conditions. Ask about treatment and visual support rather than assuming that the diagnosis has one inevitable outcome. [12]
AMD is usually painless and does not change the outward appearance of the eye, according to NHS information. Comfort therefore does not rule out active disease. New distortion or central blur still needs advice. A painful red eye, sudden major loss or a moving curtain may indicate another urgent problem and should not simply be attributed to AMD. [13]
Irish care context, specialist guidance and clinical studies. Published outcomes describe the studied populations, not this clinic’s outcomes.
Based on published clinical guidance · Last updated 29 October 2026
A conversation is a good place to start.
+353 61 52 6664 · reception@limerickeyeclinic.ie
At your pace. With your questions. For your eyes.
